These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31327684)

  • 1. Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report.
    Aradi S; Kaiser E; Cucchiara B
    J Stroke Cerebrovasc Dis; 2019 Oct; 28(10):104286. PubMed ID: 31327684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.
    Breen ID; Brumfiel CM; Patel MH; Butterfield RJ; VanderPluym JH; Griffing L; Pittelkow MR; Mangold AR
    JAMA Netw Open; 2021 Apr; 4(4):e217934. PubMed ID: 33871613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: a case report.
    Cullum CK; Olsen MK; Kocadag HB; Ashina M; Amin FM
    BMC Neurol; 2021 Jul; 21(1):257. PubMed ID: 34215196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired wound healing in a migraine patient as a possible side effect of calcitonin gene-related peptide receptor antibody treatment: A case report.
    Wurthmann S; Nägel S; Hadaschik E; Schlott S; Scheffler A; Kleinschnitz C; Holle D
    Cephalalgia; 2020 Oct; 40(11):1255-1260. PubMed ID: 32536268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Reversible Cerebral Vasoconstriction Syndrome with Large Posterior Cerebral Infarction.
    Yamada H; Kikuchi R; Nakamura A; Miyazaki H
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3043-3045. PubMed ID: 30087075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptance and Commitment Therapy (ACT) vs Erenumab for High Frequency Episodic Migraine Without Aura: Time to Take the Gloves Off!
    Grazzi L; Rizzoli P
    Headache; 2020 Apr; 60(4):804-806. PubMed ID: 32096558
    [No Abstract]   [Full Text] [Related]  

  • 8. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.
    Urits I; Jones MR; Gress K; Charipova K; Fiocchi J; Kaye AD; Viswanath O
    Curr Pain Headache Rep; 2019 Mar; 23(5):29. PubMed ID: 30874961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice.
    Mulder IA; Li M; de Vries T; Qin T; Yanagisawa T; Sugimoto K; van den Bogaerdt A; Danser AHJ; Wermer MJH; van den Maagdenberg AMJM; MaassenVanDenBrink A; Ferrari MD; Ayata C
    Ann Neurol; 2020 Oct; 88(4):771-784. PubMed ID: 32583883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: A case report.
    Naegel S; Burow P; Holle D; Stoevesandt D; Heintz S; Thaele A; Zierz S; Kraya T
    Headache; 2021 Apr; 61(4):694-696. PubMed ID: 33779998
    [No Abstract]   [Full Text] [Related]  

  • 11. Erenumab Plus Subcutaneous Immunoglobulin in a Patient With Comorbid Chronic Migraine and Myasthenia Gravis.
    Ornello R; Frattale I; Pistoia F; Sacco S; Notturno F
    Headache; 2020 Apr; 60(4):787-788. PubMed ID: 32096556
    [No Abstract]   [Full Text] [Related]  

  • 12. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
    Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
    J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erenumab in the treatment of migraine.
    Jain S; Yuan H; Spare N; Silberstein SD
    Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percheron Infarction: Is It Just a Rare Cerebrovascular Variant or a Forewarning of Severe Multiple Posterior Circulation Infarcts.
    Liu J; Xiao H; Hu Z
    J Stroke Cerebrovasc Dis; 2019 Apr; 28(4):e27-e29. PubMed ID: 30655045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erenumab: First Global Approval.
    Markham A
    Drugs; 2018 Jul; 78(11):1157-1161. PubMed ID: 29968151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyperdense posterior cerebral artery sign].
    Herrera M; Erro ME; Gállego J
    Neurologia; 2007 Apr; 22(3):182-3. PubMed ID: 17364257
    [No Abstract]   [Full Text] [Related]  

  • 17. In brief: Erenumab (Aimovig) hypersensitivity.
    Med Lett Drugs Ther; 2019 Mar; 61(1568):48. PubMed ID: 31022159
    [No Abstract]   [Full Text] [Related]  

  • 18. Endothelin-1-induced vasospasms of spiral modiolar artery are mediated by rho-kinase-induced Ca(2+) sensitization of contractile apparatus and reversed by calcitonin gene-related Peptide.
    Scherer EQ; Herzog M; Wangemann P
    Stroke; 2002 Dec; 33(12):2965-71. PubMed ID: 12468798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of CGRP in Migraine.
    Edvinsson L
    Handb Exp Pharmacol; 2019; 255():121-130. PubMed ID: 30725283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic treatment of ischaemic stroke occurring during a migrainous attack: a case report.
    Skoloudík D; Král M; Sanák D; Vlachová I; Hlustík P; Michálková K; Herzig R; Kanovsky P
    Cephalalgia; 2010 Mar; 30(3):368-72. PubMed ID: 19438912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.